Agnostic Metagenomic Next-Generation Sequencing (mNGS) for Clinical Diagnostics

The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is issuing an information‑only RFI (W911SR‑26‑R‑MNGS) to identify mature (TRL 4 +) portable metagenomic next‑generation sequencing (mNGS) systems that can provide rapid, hypothesis‑free identification of viral, bacterial, fungal, and parasitic pathogens—including traditional, novel, engineered, and emerging agents—from human clinical samples in far‑forward or forward‑laboratory settings. Desired solutions are backpack‑sized, battery‑operable, environmentally robust, and must include automated quality filtering, host‑subtraction, taxonomic classification with validated reporting thresholds, and optional host‑transcriptome biomarker analysis. Respondents must submit a ≤5‑page white paper and a 1‑page quad chart covering the project objective, product benefit, high‑level development schedule, ROM cost, and IP/data‑rights stance; the government will prioritize technical approach, product maturity, and bioinformatics/clinical interpretation. In parallel, CPE CBRND seeks independent Test & Evaluation (T&E) partners capable of validating such mNGS diagnostics. T&E firms should provide a ≤2‑page white paper describing corporate experience with regulated molecular diagnostics, laboratory biosafety capabilities, FDA‑focused regulatory and validation expertise (EUA, 510(k), de novo, CLIA waiver), and past performance for government or industry. Additional information on manufacturing capacity, scalability, and reagent shelf‑life is also requested. All responses are to be emailed to usarmy.detrick.cpe‑cbrnd.mbx.baa@army.mil with the appropriate subject line; unsolicited proposals will not be considered.

Notice ID

f4603fb6594d4933b4083b2e95289d61

Solicitation Number

W911SR-26-R-MNGS

NAICS Code

N/A

Classification Code

N/A